Why is the investment clawback failing to attract clinical trials?
The investment clawback mechanism is proving ineffective as a tool for stimulating clinical research, despite its success in attracting manufacturing facilities. According to the Hellenic Association of Pharmaceutical Companies (HAPPhy), the current framework focuses heavily on productive investments—such as the construction and upgrading of manufacturing plants—rather than the specialized requirements of clinical studies. The mechanism operates by offsetting pharmaceutical investments against the mandatory clawback returns required when drug budget limits are exceeded, a structure that does not align with the operational realities of clinical research.
HAPPhy representatives have highlighted that while the measure has successfully encouraged the expansion of production sites, it lacks the specific incentives necessary to bring high-value clinical trials to Greek soil. This misalignment creates a strategic bottleneck, where the country gains industrial capacity but loses out on the high-tech, innovation-driven sector of clinical research.
The distinction between manufacturing and research incentives
The primary issue lies in the nature of the investment. Manufacturing investments are tangible, long-term, and capital-intensive, making them easier to capture through traditional clawback offsets. Clinical trials, however, are service-oriented and highly mobile; they gravitate toward environments with streamlined regulatory frameworks, specialized medical expertise, and specific fiscal advantages that prioritize research over production. By using a tool designed for the former to solve the needs of the latter, the Greek government is missing the opportunity to capture the most innovative segment of the pharmaceutical market.
How much funding has been lost to the decline in clinical trials?
The decline in the absorption of funds for clinical trials in Greece is statistically significant and follows a downward trajectory. In 2021, clinical trials absorbed €50 million out of a total available €100 million. By 2023, this figure plummeted to just €5.5 million out of €125 million. Most recently, in 2025, the absorption dropped to a mere €2.5 million from a €100 million total. These figures illustrate a diminishing return on the current incentive structures.
The economic cost of this trend is estimated to be over €1 billion annually. This represents the lost opportunity cost of not attracting the volume of clinical trials that the Greek institutional framework should theoretically support. The gap between actual and potential investment is staggering when compared to European peers.
| Country | Annual R&D Investment (Approx.) |
|---|---|
| Europe (Total) | €53 billion |
| Belgium | €6 billion |
| France | €5.4 billion |
| Hungary | €305 million |
| Greece (Actual) | €100 million |
| Greece (Population-adjusted Potential) | €1.2 billion |
What is the impact of low clinical trial numbers on patient access?
Patients in Greece are facing significantly restricted access to cutting-edge medical treatments due to the lack of local clinical research. HAPPhy warns that the combination of heavy taxation, mandatory clawback returns, and low initial drug pricing results in patients having access to only about 20% of new, innovative medicines. When clinical trials are absent, the pipeline for bringing new therapies into the national healthcare system is severely constricted.
Clinical trials serve as a critical bridge for patient care. Participants in these studies gain access to innovative drugs that may not be widely available for another 5 to 10 years. Furthermore, these patients benefit from continuous, high-level monitoring by specialized healthcare professionals, ensuring a level of care that is often superior to standard treatments during the trial period.
The dual benefit of clinical research for patients and the state
Beyond direct medical access, clinical trials provide a significant economic subsidy to the National Health System (NHS). Pharmaceutical companies provide the experimental therapies—which are often extremely expensive—to participants free of charge. This direct provision of high-cost medication helps the state manage its budget while still offering patients life-saving options. Without these trials, the financial burden of providing such innovative treatments would fall entirely on the public purse.
How do clinical trials benefit the Greek national economy?
Clinical trials act as a direct conduit for foreign investment into the Greek public health system. Unlike manufacturing investments, which are infrequent and require massive capital outlays and complex criteria, clinical trials represent a continuous and steady stream of international capital. This funding flows directly into hospitals, supporting highly skilled medical researchers, doctors, and specialized administrative staff.
The economic impact is multifaceted, touching several sectors of the national economy:
- Direct Healthcare Funding: Inflow of foreign capital into public hospitals and research institutions.
- Human Capital Development: Support for specialized medical professionals and researchers.
- Continuous Investment: A recurring revenue stream compared to the sporadic nature of industrial construction.
- Innovation Ecosystem: Strengthening the country's position within the European R&D landscape.
HAPPhy has repeatedly submitted proposals to the Ministries of Health, Development, and National Economy, as well as to the Prime Minister's office, to address these issues. However, the association notes that despite these efforts, no significant policy changes have been implemented to rectify the current imbalance.
Frequently asked questions
What is the pharmaceutical clawback in Greece?
The pharmaceutical clawback is a mechanism where pharmaceutical companies must return a portion of their revenue to the state when the total spending on medicines exceeds the predefined national budget. The "investment clawback" is a specific measure intended to allow companies to offset these returns against new investments made within the country.
Why does Greece attract less R&D than its population suggests?
Greece currently attracts approximately €100 million in pharmaceutical R&D annually. However, based on its 2.3% share of the European population, the country should theoretically attract €1.2 billion. The discrepancy is attributed to an ineffective institutional framework and fiscal policies that favor production over research.
How do clinical trials help the National Health System?
Clinical trials provide free, innovative, and often expensive medications to participants, which reduces the direct cost to the National Health System. Additionally, they bring foreign investment directly into hospitals and support the training and employment of highly specialized medical researchers and staff.
What is the difference between productive and clinical investment?
Productive investment refers to the construction or upgrading of physical manufacturing facilities. Clinical investment refers to the funding of medical research and trials. The current Greek clawback system is highly effective at attracting the former but fails to provide the necessary incentives for the latter.
How long does it take for trial drugs to reach the general market?
Typically, a drug that is currently being studied in a clinical trial will take between 5 and 10 years to undergo the full regulatory process and become widely available to the general patient population.
